NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Antimicrobial Resistance and Modernising Microbiology > New TB test to get sufferers on right drugs sooner

New TB test to get sufferers on right drugs sooner

24 June 2015 · Listed under Antimicrobial Resistance and Modernising Microbiology, Gastroenterology and Mucosal Immunity, Genomic Medicine

Tuberculosis sufferers will be able get drug treatment sooner thanks to a new whole genome sequencing technique to determine for the first time which drugs to give sufferers, researchers in Oxford have reported.

University of Oxford researchers at the John Radcliffe Hospital have developed a genetic test – details of which are published online today in the Lancet Infectious Diseases – that can detect which drugs will effectively treat people with the disease and those that will not.

From 1948, the only way to test for drug resistance was to run laboratory tests on sufferers’ sputum, a process which could take up to six weeks, delaying potentially lifesaving treatment.

In the last two decades genetic tests targeted at small sections of the TB DNA have been able to tell doctors what drugs to rule out.

However, medics would still carry out time-consuming laboratory test to be sure of their results.

The new test studied the whole TB genome – its entire DNA code – to identify mutations that cause drug resistance and those that don’t.

It means doctors will be able to rule out but also, for the first time, rule in which drugs to give to sufferers without the need for a lengthy laboratory culture test. The test will return results in about three weeks.

This will speed up diagnosis of sufferers, particularly in developing countries where TB rates are highest, so they get the right drugs sooner.

The test is being trialled in the Midlands by Public Health England and, if successful, it is hoped it will be rolled out across the country.

The new technique also means new mutations in TB DNA can be identified and added to an ever expanding catalogue of mutations that have been characterised as either causing drug resistance or not.

The two-and-a-half year study is the biggest ever of its kind and comprised more than 3,600 samples from the UK, including Oxford, Germany, Uzbekistan, Sierra Leone and South Africa.

It was led by the NIHR Oxford Biomedical Research Centre (BRC), based at Oxford’s Churchill Hospital; Public Health England; the German Centre for Infection Research in Borstel, and the South African National Institute for Communicable Diseases.

Most patients with TB live in low-income countries where the basic laboratory facilities required to perform culture are often lacking.

Misdiagnosing drug resistance risks onward transmission and patient deaths but there are hopes the test can be developed into an affordable, hand-held device for use around the world.

Lead investigator Professor Tim Peto, of the Oxford BRC and a consultant in infectious diseases at the Churchill and John Radcliffe Hospital, said:  “This is the beginning of the end for routine laboratory culture for TB drug resistance.

“We are moving from 130 years of culturing TB to a new digital era in microbiology. It is particularly exciting for low-income settings where the lack of laboratories currently leads to under diagnosis of drug resistance. These results pave the way for mobile genetic sequencing technologies to bypass such obstacles to better patient care.”

“This work provides the foundation for a new era in TB diagnostics.”

Co-investigator Prof. Stefan Niemann, leading the Molecular Mycobacteriology Unit at theResearch Center Borstel, described the findings as “a paramount change opening the way to treat multi-drug resistant TB patients better”.

There are about nine million global TB cases each year and 1.5-million deaths. There were 7,892 UK cases in 2013 with up to 334 deaths in 2012.

A multi-drug resistant strain of the disease affects about 480,000 people globally, for which treatment can last two years and lead to side effects including nausea, deafness, liver toxicity and psychosis.

The World Health Organization (WHO) aims to stop TB by 2035, a target that will not be met without improvements in the diagnosis of drug resistance.

For further information contact Oliver Evans, Communications Manager (Research and Development), Oxford University Hospitals NHS Trust on 07747 456443 or the media team at the trust on 01865 223070.

← Immune system talk draws crowds
Recruitment begins on major genetics project →

News

  • Lymph nodes reveal more about mechanisms of autoimmunity 14 June 2022
  • Conference aims to forge collaborations to tackle dementia 9 June 2022
  • Lung function device wins top chemistry Prize 8 June 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre